Theralase Technologies (CVE:TLT) Sets New 12-Month Low at $0.16

Theralase Technologies Inc. (CVE:TLTGet Free Report)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.16 and last traded at C$0.16, with a volume of 61820 shares traded. The stock had previously closed at C$0.16.

Theralase Technologies Price Performance

The company has a debt-to-equity ratio of 25.07, a quick ratio of 3.40 and a current ratio of 1.22. The company has a market capitalization of C$37.62 million, a PE ratio of -8.00 and a beta of 1.66. The company’s 50-day simple moving average is C$0.19 and its 200-day simple moving average is C$0.20.

Theralase Technologies Company Profile

(Get Free Report)

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

Featured Stories

Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.